Renol Polychem IPO GMP & Subscription status

Core Business & Overview

Renol Polychem Limited, incorporated in 2008 and based in Rajkot, Gujarat, is a manufacturer and supplier of masterbatches and polymer additives. Its product portfolio includes:

• Colour masterbatches (black, white, fluorescent, metallic, transparent, etc.)
• Filler masterbatches (talc, calcium carbonate, transparent)
• Additive masterbatches (UV stabilizers, antioxidants, processing aids, slip agents, flame retardants)
• Polymer compounds and pigments, plus impact modifiers and other specialty products

Renol serves a wide range of industries including UPVC/CPVC pipe manufacturers, packaging, automotive components, electronics, textiles, consumer goods, and agricultural films. Operating a state-of-the-art manufacturing facility equipped with co‑rotating twin‑screw extruders, it emphasizes consistent control, high dispersion quality, and reduced wastage.

Strengths

1. Diversified & Customised Product Range
   Offers an extensive array of products—color, filler, additive masterbatches, polymer compounds—tailored per industry needs. This enables serving clients across automotive, packaging, consumer goods, and more.
2. Experienced, Operationally Savvy Management
   Led by founder and MD Bhaveshbhai Mansukhbhai Harsoda, with over 15 years of technical and procurement expertise. Supported by Naitik Bhaveshbhai Harsoda driving marketing and finance.
3. Quality and Manufacturing Efficiency
   Utilizes high-torque twin‑screw extruders dedicated to specific color runs, enabling superior dispersion, consistency, minimal waste, and lower cost passed to clients.
4. Growth-focused and Sustainability-oriented
   Actively developing eco‑friendly polymer solutions via its R&D efforts and aligning with global sustainability trends.

Potential Risks

1. Regulatory and Environmental Risk
   The company operates in the plastics/polymers sector, which faces increasing regulatory scrutiny and environmental regulations (e.g. on single‑use plastics, waste management), potentially affecting operations.
2. Operational Risk from Capacity Constraints
   As an SME with a single production site, any disruption—mechanical breakdown, supply chain issues, or compliance issues—can significantly impact output and revenues.
3. Financial Leverage & Limited Scale
   The firm carries notable debt levels relative to equity (total borrowings ₹5.28 crores as of May 2025 vs. net worth ~₹14.5 crores). Its relatively small scale and thin margins can limit financial flexibility.
4. High Competition & Margin Pressure
   The plastics additives industry is competitive with established large‑scale players. Smaller firms like Renol may face pricing pressure and lower margins due to economies of scale.

Financial Performance Overview (₹ in Crore)

Revenue

• FY 2023: ₹41.67 Cr – A solid revenue base before a dip.
• FY 2024: ₹6.45 Cr – Sharp decline, possibly due to restructuring, capacity limitation, or operational disruption.
• FY 2025: ₹62.30 Cr – Massive recovery and growth; shows strong business revival and expansion.

Profit

• FY 2023: ₹0.73 Cr – Moderate profit.
• FY 2024: ₹1.53 Cr – Despite low revenue, profit more than doubled, indicating cost optimization or better margins.
• FY 2025: ₹5.00 Cr – Significant jump in profitability, showing strong financial performance.

Total Assets

• FY 2023: ₹10.27 Cr – Moderate asset base.
• FY 2024: ₹15.49 Cr – Growth of ~50%, likely due to reinvestments and capex.
• FY 2025: ₹23.41 Cr – Continued asset build-up to support expansion.

✅ Pros

• Diversified masterbatch product range with applications across multiple industries.
• Strong FY25 revenue and profit growth shows business recovery and scalability.
• Experienced management with domain expertise.
• Use of IPO funds focused on expansion and debt reduction.

❌ Cons

• FY24 revenue dip raises questions on business consistency.
• Operates in a highly competitive, price-sensitive industry.
• SME IPO with relatively low liquidity and higher risk for retail investors.
• Single manufacturing location increases operational risk.